Journal of Thrombosis and Haemostasis 2026; 24(1): 79-87
Efanesoctocog alfa is a high-sustained factor (F)VIII replacement therapy for hemophilia A. The D'D3 domain of efanesoctocog alfa overcomes the von Willebrand factor–imposed half-life ceiling and... HTML Version |
PDF Version
|
Print the excerpt
Journal of Thrombosis and Haemostasis 2026; 24(2): 408-17
Bleeding complications are frequent under left ventricular assist device (LVAD) support. LVAD-associated high shear stress induces increased proteolysis of circulating von Willebrand factor (VWF), which... HTML Version |
PDF Version
|
Print the excerpt
Research and Practice in Thrombosis and Haemostasis 2026; 10(1): 103327
Long-term von Willebrand factor (VWF) prophylaxis is recommended for people with von Willebrand disease (VWD) who experience frequent and severe bleeds. However, repeated administration of VWF-containing... HTML Version |
PDF Version
|
Print the excerpt
Research and Practice in Thrombosis and Haemostasis 2026; 10(2): 103383
Multiple studies conducted between 1990s and 2010s reported increased rates of postpartum hemorrhage (PPH) among women with von Willebrand disease (VWD), even with specialized peripartum care. To generate... HTML Version |
PDF Version
|
Print the excerpt
By requesting access to the "WillebrandXPERT" service, I agree that GNM Healthcare Group Companies USA, Inc. may use the data acquired during my access request to provide me with weekly
information related to its services in accordance with the
Privacy Policy.
You have the right to access, rectify and delete your data, which you can exercise by sending your request to
dpo@gnmhealthcare.com.
You can exercise your right to object by requesting the deletion of your data at any time by clicking on the "Delete my data" link.
